Keystone Symposia

This meeting took place in 2017

Here are the related meetings in 2020:
Antibodies as Drugs: From B Cell Biology to New Treatments (B1)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies (A7)

Organizer(s) CheriƩ L. Butts, Amy S. Rosenberg, Amy D. Klion and Sachdev S. Sidhu
January 22—26, 2017
Snowbird Resort • Snowbird, UT USA
Discounted Abstract Deadline: Sep 21, 2016
Abstract Deadline: Oct 20, 2016
Scholarship Deadline: Sep 21, 2016
Discounted Registration Deadline: Nov 21, 2016

Sponsored by Genmab A/S, ImmunoGen, Inc., Merck & Co., Inc., Mersana Therapeutics, Pfizer Inc. and Roche

Summary of Meeting:
The purpose of this meeting is to examine different approaches for treatment of cancer and other diseases (e.g., fibrosis, autoimmunity and inflammatory diseases). The program will provide insights from academic and industry scientists on innovative biologics technologies and treatment strategies for ameliorating disease in an effort to identify synergies and opportunities to cross-fertilize approaches. Furthermore, the meeting includes perspectives from the US Food & Drug Administration and how the outlined strategies will impact the drug review and approval process. The intention is to better inform meeting attendees of current/future strategies for treating disease and best practices for transforming concepts into approved drugs.

View Meeting Program


National Institute of Allergy and Infectious Diseases (NIAID)/National Center for Advancing Translational Sciences (NCATS) Scholarship Recipients

Ken G. Andersson
Royal Institute of Technology, Sweden

Kalie Mix
Sanofi, USA

Samuel Pollock
University of California, San Francisco, USA

Anna-Luisa Volk
Royal Institute of Technology, KTH, Sweden

Ellen Wagner
University of Texas at Austin, USA